Invion Limited (ASX:IVX)

Australia flag Australia · Delayed Price · Currency is AUD
0.0790
+0.0010 (1.28%)
Mar 4, 2026, 3:47 PM AEST
Market Cap6.68M -40.7%
Revenue (ttm)-1.07K
Net Income-10.50M
EPS-0.13
Shares Out85.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,080
Average Volume102,407
Open0.0790
Previous Close0.0780
Day's Range0.0790 - 0.0790
52-Week Range0.0750 - 0.2000
Beta0.86
RSI40.18
Earnings DateMar 2, 2026

About Invion

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical... [Read more]

Sector Healthcare
Founded 2000
Employees 4
Stock Exchange Australian Securities Exchange
Ticker Symbol IVX
Full Company Profile

Financial Performance

Financial Statements